« Back to Record
Citation APA

Girard, N., Ponce Aix, S., Cedres, S., Berghmans, T., Burgers, S., Toffart, A.-C., Phalke, S. P., Janssens, A., Gervais, R., Hochstenbag, M., Cardoso da Silva, M., Burger, I. A., Prosch, H., Stahel, R., Xenophontos, E., Pretzenbaher, Y., Neven, A., & Peters, S. (2023). Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open, 8(3), 101576. doi:10.1016/j.esmoop.2023.101576


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/362468

Girard, N., Ponce Aix, S., Cedres, S., Berghmans, T., Burgers, S., Toffart, A.-C., Phalke, S. P., Janssens, A., Gervais, R., Hochstenbag, M., Cardoso da Silva, M., Burger, I. A., Prosch, H., Stahel, R., Xenophontos, E., Pretzenbaher, Y., Neven, A., & Peters, S. (2023). Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open, 8(3), 101576. doi:10.1016/j.esmoop.2023.101576